Japan-based Mochida Pharmaceutical and LG Chem, based in South Korea, have entered into a partnership agreement for Dinagest, which is sold by Mochida in Japan and is indicated for endometriosis and other conditions.
Under this agreement, Mochida has granted LG Chem the exclusive rights to develop and market the Product in South Korea and Thailand. LG Chem will obtain the required marketing authorisations in each country and subsequently make the product available to patients.
Dienogest, the active ingredient in Dinagest, is a progestin that suppresses ovarian function and inhibits the proliferation of endometrial cells through its selective agonist activity for the progesterone receptor.
Mochida launched the product in Japan in 2008 and has been exploring opportunities for its expansion into overseas markets. Furthermore, Mochida has been promoting its global expansion toward 2031, and as part of these efforts, Mochida is moving forward with the first global expansion of the product through the conclusion of this agreement.
In the field of reproductive medicine, LG Chem has built over three decades of specialised expertise in the research and manufacturing of hormone-based therapies for infertility treatment. Through global-standard quality, ongoing R&D, and a strong commitment to patients and physicians, LG Chem continues to be a trusted partner in the field of reproductive medicine.
Mochida and LG Chem have previously entered into a partnership agreement regarding biosimilars of etanercept and adalimumab, which were subsequently launched in Japan. Under the newly concluded agreement, Mochida and LG Chem aim to deliver the product to patients in South Korea and Thailand and contribute to improving their quality of life.
